BACKGROUND: An important aspect of Alzheimer's disease (AD) is loss or impairment of cholinergic neurons. It is controversial whether there is a similar cholinergic impairment and cerebral deficit of acetylcholine (ACh) in the case of vascular dementia (VD). The purpose of this study was to explore the levels of ACh and choline (Ch) in the cerebrospinal fluid (CSF) of patients with AD and VD, and their possible relationship with cognitive impairment. METHODS: Twenty-two AD patients, twenty-two VD patients, and twenty normal controls were recruited and scored with a Mini-Mental State Examination (MMSE). CSF concentrations of ACh and Ch were measured using high-performance liquid chromatography with an electrochemical detector (HPLC-ECD) and the results were then compared to cognitive status. RESULTS: ACh concentrations in CSF of AD patients [(10.7 +/- 5.1) nmol/L] and VD patients [(16.8 +/- 7.4) nmol/L] were both significantly lower than in controls [(34.5 +/- 9.0) nmol/L, t = 10.67, P < 0.001; t = 6.91, P < 0.001]. Both results correlated positively with MMSE scores (rs = 0.88 and rs = 0.85, respectively, P < 0.01). The CSF concentration of Ch was significantly higher in VD patients [(887.4 +/- 187.4) nmol/L] compared to AD patients [(627.6 +/- 145.1) nmol/L, t = 6.4, P < 0.001] and controls [(716.0 +/- 159.4) nmol/L, t = 4.2, P = 0.002]. CSF Ch concentration showed no difference between AD patients and normal controls, nor did it correlate with MMSE score in any of the three groups. CONCLUSIONS: The positive correlation between ACh deficit and cognitive impairment suggests that ACh is an important neurotransmitter for memory. The similar decrease in ACh concentration in AD and VD patients may imply a similar pathogenesis for the process of cognitive impairment involved in these two disorders. The elevated CSF levels of Ch in VD patients compared to AD patients may be useful diagnostically. Cholinesterase inhibitors may be helpful not only for AD patients, but also for VD patients.
BACKGROUND: An important aspect of Alzheimer's disease (AD) is loss or impairment of cholinergic neurons. It is controversial whether there is a similar cholinergic impairment and cerebral deficit of acetylcholine (ACh) in the case of vascular dementia (VD). The purpose of this study was to explore the levels of ACh and choline (Ch) in the cerebrospinal fluid (CSF) of patients with AD and VD, and their possible relationship with cognitive impairment. METHODS: Twenty-two ADpatients, twenty-two VD patients, and twenty normal controls were recruited and scored with a Mini-Mental State Examination (MMSE). CSF concentrations of ACh and Ch were measured using high-performance liquid chromatography with an electrochemical detector (HPLC-ECD) and the results were then compared to cognitive status. RESULTS:ACh concentrations in CSF of ADpatients [(10.7 +/- 5.1) nmol/L] and VD patients [(16.8 +/- 7.4) nmol/L] were both significantly lower than in controls [(34.5 +/- 9.0) nmol/L, t = 10.67, P < 0.001; t = 6.91, P < 0.001]. Both results correlated positively with MMSE scores (rs = 0.88 and rs = 0.85, respectively, P < 0.01). The CSF concentration of Ch was significantly higher in VD patients [(887.4 +/- 187.4) nmol/L] compared to ADpatients [(627.6 +/- 145.1) nmol/L, t = 6.4, P < 0.001] and controls [(716.0 +/- 159.4) nmol/L, t = 4.2, P = 0.002]. CSF Ch concentration showed no difference between ADpatients and normal controls, nor did it correlate with MMSE score in any of the three groups. CONCLUSIONS: The positive correlation between ACh deficit and cognitive impairment suggests that ACh is an important neurotransmitter for memory. The similar decrease in ACh concentration in AD and VD patients may imply a similar pathogenesis for the process of cognitive impairment involved in these two disorders. The elevated CSF levels of Ch in VD patients compared to ADpatients may be useful diagnostically. Cholinesterase inhibitors may be helpful not only for ADpatients, but also for VD patients.
Authors: Romina M Uranga; Annadora J Bruce-Keller; Christopher D Morrison; Sun Ok Fernandez-Kim; Philip J Ebenezer; Le Zhang; Kalavathi Dasuri; Jeffrey N Keller Journal: J Neurochem Date: 2010-05-06 Impact factor: 5.372
Authors: Peter Riederer; Amos D Korczyn; Sameh S Ali; Ovidiu Bajenaru; Mun Seong Choi; Michael Chopp; Vesna Dermanovic-Dobrota; Edna Grünblatt; Kurt A Jellinger; Mohammad Amjad Kamal; Warda Kamal; Jerzy Leszek; Tanja Maria Sheldrick-Michel; Gohar Mushtaq; Bernard Meglic; Rachel Natovich; Zvezdan Pirtosek; Martin Rakusa; Melita Salkovic-Petrisic; Reinhold Schmidt; Angelika Schmitt; G Ramachandra Sridhar; László Vécsei; Zyta Beata Wojszel; Hakan Yaman; Zheng G Zhang; Tali Cukierman-Yaffe Journal: J Neural Transm (Vienna) Date: 2017-08-01 Impact factor: 3.575
Authors: Nick van Wijk; Rosalinde E R Slot; Flora H Duits; Marieke Strik; Egbert Biesheuvel; John W C Sijben; Marinus A Blankenstein; Jörgen Bierau; Wiesje M van der Flier; Philip Scheltens; Charlotte E Teunissen Journal: Alzheimers Dement (Amst) Date: 2017-05-16
Authors: Michał Kosowski; Joanna Smolarczyk-Kosowska; Marcin Hachuła; Mateusz Maligłówka; Marcin Basiak; Grzegorz Machnik; Robert Pudlo; Bogusław Okopień Journal: Molecules Date: 2021-05-11 Impact factor: 4.411
Authors: Willem Johan van den Brink; Semra Palic; Isabelle Köhler; Elizabeth Cunera Maria de Lange Journal: Pharm Res Date: 2018-02-15 Impact factor: 4.200